
San Diego-based Neuropore Therapies develops disease-modifying treatments for neurodegenerative disorders.
Neuropore Therapies, founded in San Diego, CA, is dedicated to discovering and developing disease-modifying treatments for neurodegenerative disorders such as Parkinson’s and Alzheimer’s diseases. Their mission is to halt the progression of these diseases by targeting their underlying causes, specifically the pathological accumulation of misfolded and aggregated neurotoxic proteins. Neuropore's therapeutic candidates are designed to address these fundamental issues, with a focus on early-stage interventions.
Notable affiliations include a grant from The Michael J. Fox Foundation for Parkinson’s Research, which supports the development of Neuropore's TLR2 program. Key achievements include ongoing clinical trials, such as UCB0599 for early-stage Parkinson’s disease. The company has made significant strides in the field of neurodegenerative research, contributing valuable insights and potential treatments that aim to improve patient outcomes and quality of life.

NeuroTherapeutics Pharma

Orphan Star Therapeutics

Mojave Pharma

Neurolink

Aspen Neuroscience

Intellect Neurosciences

VersaPeutics

Neuro42

Neurona Therapeutics

Neurelis
neurelis.com

Neurocarrus
neurocarrus.com

Neuraptive Therapeutics
neuraptive.com

NeuroGenetic Pharmaceuticals

Embera Neurotherapeutics
emberaneuro.com

Neurodon
neurodon.net
Companies similar to Neuropore Therapies include NeuroTherapeutics Pharma, Orphan Star Therapeutics, Mojave Pharma and Neurolink.
Neuropore Therapies was founded in 2008.
Neuropore Therapies' headquarters is located in San Diego, CA, US.
Neuropore Therapies' most recent funding round was for $500k (USD) in February 2020.
As of Feb 17, 2020, Neuropore Therapies has raised a total of $500k (USD).
Neuropore Therapies has 13 employees as of Feb 4, 2024.